A case-control, retrospective study to investigate the risk factors for subconjunctival hemorrhage associated with intravitreal injection of Ranibizumab.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2016
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Diabetic retinopathy; Retinal oedema
- Focus Adverse reactions
- 27 Feb 2016 New trial record